What is the current state of the pharmacological arsenal designed to extend the human lifespan? What is actually being tested in humans, what is still locked in mouse models, what is genuinely speculative—and what is scientifically fringe?
Here is the inventory. Tiers, as always. Evidence, safety, and accessibility.
Tier 1: In Human Clinical Trials, With Published Data
These are the interventions that have crossed the threshold from preclinical promise into human testing. They are not approved for aging—no regulatory body recognizes aging as an indication—but they are being tested in humans, with endpoints that matter.
Rapamycin and Rapalogs. The mTOR inhibitor rapamycin is the most robust pharmacological lifespan extender in mice. In humans, the picture is more complicated. A randomized, double-blind, placebo-controlled trial of low-dose rapamycin in frail older adults with heart failure with preserved ejection fraction found no significant improvement in physical performance, frailty, quality of life, or inflammatory markers after 26 weeks—though it did significantly improve some metabolic markers of poor health. The RAP PAC study is now seeking to identify safe and effective weekly doses of sirolimus and everolimus that intervene on the fundamental biology of aging. UT Health San Antonio has launched a multi-phase clinical study to examine dosing, safety, and long-term effects in generally healthy adults aged 65 to 90. Rapamycin is Tier 1 for human testing, Tier 3 for demonstrated lifespan extension.
Senolytics. Senescent cells accumulate with age and secrete a pro-inflammatory cocktail that drives tissue dysfunction. Senolytics selectively clear these cells. The most dramatic recent result comes from a Phase 2, double-blind, randomized, placebo-controlled trial of intermittent dasatinib plus quercetin in fibrotic metabolic dysfunction-associated steatohepatitis. The primary endpoint—at least one stage of fibrosis improvement without MASH worsening on paired liver biopsies—was achieved in 47% of treated participants versus 7% with placebo. MASH resolution occurred in 53% versus 7%. A separate randomized pilot trial of fisetin in CVID-associated granulomatous-lymphocytic interstitial lung disease found that fisetin was well tolerated and showed benefit in diffusion capacity, lung volumes, and mental health–related outcomes compared to placebo. Senolytics are Tier 1 for safety, Tier 2 for efficacy.
NAD+ Precursors (Nicotinamide Riboside, NMN). A randomized, double-blind, placebo-controlled Phase I trial of reduced nicotinamide mononucleotide calcium salt (NMNH-Ca) in healthy adults aged 40–65 found that it was well tolerated at all doses, with no serious adverse events, and that whole-blood NAD+ increased in a dose-related pattern. But a Phase II randomized controlled pilot study of nicotinamide riboside in older adults with amnestic mild cognitive impairment found that NR effectively raised NAD+ twofold but did not improve cognitive function, total cerebral blood flow, or blood pressure over 12 weeks. Tier 1 for safety and biomarker elevation. Tier 3 for meaningful clinical benefit in healthy adults.
Mesenchymal Stem Cells (MSCs) for Frailty. A randomized Phase 2b dose-escalation trial of laromestrocel—human bone marrow-derived allogeneic MSCs—in aging frailty found that performance on the six-minute walk test improved in a dose-response fashion. A separate Phase 2, single-centre, randomized, open-label controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty found no therapy-related serious adverse events and higher Short Physical Performance Battery scores in the treatment group. Tier 1 for functional endpoints. Tier 2 for durability and long-term safety.
Klotho Gene Therapy. A Phase 1 trial is evaluating the safety and efficacy of injectable Klotho plasmid gene therapy in healthy adult volunteers, delivered via a nonviral plasmid—not a virus—with the hypothesis that Klotho may improve cognitive function, kidney function, healthspan, and lifespan. Klothea Bio has launched a Phase 1b trial of AKL003, an alpha-Klotho mRNA therapeutic in lipid nanoparticles, in healthy adults. Tier 1 for novelty. Tier 3 for evidence.
OSK Partial Reprogramming (ER-100). The FDA cleared a trial of ER-100 from Life Biosciences in early 2026. The therapy delivers inducible expression of Oct4, Sox2, and Klf4—OSK, the Yamanaka factors without c-Myc—to partially reprogram retinal ganglion cells in patients with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. The first participant was dosed in June 2026. The risk of teratoma formation if reprogramming overshoots is not hypothetical. Tier 1 for audacity. Tier 4 for safety.
Tier 2: In Preclinical Research, With Strong Animal Data
Metformin. The TAME trial was designed to test whether metformin delays the development or progression of age-related chronic diseases. But as of mid-2026, TAME has still not enrolled a single participant. It remains unpublished nine years after launch, awaiting funding. Tier 2: the trial is the evidence. Until it runs, the human data are observational.
Mitochondrial Transplantation. Mitrix Bio has announced the successful completion of preliminary Phase 1 safety trials involving large infusions of transplanted mitochondria in a small group of senior participants. A 91-year-old physicist became the oldest human subject to receive an escalating dose of these transplants under a “Right-to-Try” clinical framework in May 2026. Tier 2: mechanistically elegant, translation pending.
Gut Microbiome Interventions. The ARMOR study is evaluating fecal microbiota transplantation from young physically active donors to promote resilient aging in older adults. The VITAL trial is evaluating Bifidobacterium adolescentis (iVS-1) supplementation in adults aged 40–75. Tier 2: promising, but donor selection and durability are unresolved.
Epigenetic Clock Reversal. The TRIIM trial showed a mean 1.5-year epigenetic age reduction over 12 months, and the CALERIE trial demonstrated a 2–3% reduction in aging pace via DunedinPACE from modest caloric restriction. Tier 2: the biomarker moves, the outcome is unproven.
mRNA Therapeutics: The Instruction Manual, Not the Machine. Most longevity interventions work by delivering a thing—a drug, a protein, a cell. mRNA works differently. It delivers an instruction. You inject a lipid nanoparticle carrying a short-lived genetic message into the bloodstream, the message is taken up by cells, and those cells briefly manufacture whatever protein the message encodes. Then the message degrades. The effect is transient by design.
This is the platform that produced the COVID vaccines, and its therapeutic potential goes far beyond infectious disease. The reason it matters for aging is simple: aging is characterized by the decline of specific proteins—Klotho, elastin, trophic factors that maintain immune function—and mRNA offers a way to replace those proteins without permanently altering the genome. You do not need gene therapy’s viral vectors or its integration risks. You need a lipid bubble and a sequence.
The most advanced mRNA longevity trial is already running. Klothea Bio initiated a Phase 1b study of AKL003—an intravenous alpha-Klotho mRNA therapeutic formulated in lipid nanoparticles—in 21 healthy adults aged 25 to 75. Alpha-Klotho is a longevity-associated protein involved in mineral metabolism, oxidative stress, inflammation, fibrosis, cellular senescence, and neurovascular homeostasis. It declines with age, and raising it systemically has been notoriously difficult with recombinant protein or gene therapy approaches. The core bet is that transient mRNA delivery can achieve controllable, repeatable “hormone-like” supplementation of a secreted protein. The trial is single-site, running in a special jurisdiction in Honduras, with two doses four weeks apart and a broad exploratory panel spanning inflammation, metabolic status, mitochondrial function, sleep metrics, and cognitive assessments. It is not a cure. It is a proof of pharmacology. But it is a proof being tested in humans right now.
The preclinical work is broader than Klotho. A 2025 Nature paper showed that the liver can be transiently repurposed to restore age-diminished immune cues. Researchers identified Notch and FLT3L pathways, together with interleukin-7 signaling, as declining with age. They then delivered mRNAs encoding DLL1, FLT3L, and IL-7 to hepatocytes in aged mice. The result: expanded common lymphoid progenitors, boosted thymopoiesis, replenished T cells, and enhanced dendritic cell function. Treatment improved vaccine responses and restored antitumour immunity. Crucially, the effects were reversible after dosing ceased and did not breach self-tolerance—unlike recombinant cytokine treatments, which carry inflammatory and autoimmune liabilities. This is not gene therapy. It is a transient reprogramming of the liver’s secretory output.
The same logic applies to senescence and inflammation. A 2026 study in Protein & Cell demonstrated that repeated doses of mRNA-LNP in mice did not trigger chronic elevation of IL-6, TNF-α, IL-1β, or IFN-γ, and did not induce an adverse senescence-associated secretory phenotype cascade. A separate 2026 paper showed that an mRNA-LNP system delivering tropoelastin—the precursor to elastin—induced de novo elastogenesis and counteracted both UVB-induced and D-galactose-mimicked skin aging. Elastin production ceases in adults, and its loss is irreversible with current tools. The mRNA instruction reopens a door that biology closed decades ago.
And then there is the circular mRNA platform. Insilico Medicine launched a “Longevity Vaccines” research program that uses circular mRNA packaged in targeted lipid nanoparticles to transiently encode effector programs in vivo, redirecting endogenous T cells to ablate predefined pathogenic cell subsets—starting with senescent lymphocytes. Circular mRNA is more stable than linear mRNA, which means the instruction lasts longer before degrading. The initial indication is immune rejuvenation through senescent cell clearance. The same delivery chassis is being positioned for fibrosis, autoimmunity, and metabolic dysfunction. No clinical timeline has been disclosed. It is early-stage research.
Emerging mRNA therapies are a genuine, investable field of research.
Tier 3: Speculative—But Not Crazy
These are interventions where the mechanism is plausible, the preclinical data are interesting, and the human evidence is either absent or very preliminary—but the idea is not fraud. The distinguishing feature of Tier 3 is not that it is wrong. It is that no one knows yet whether it is right.
Telomerase Activation (TA-65). A meta-analysis of 8 randomized controlled trials (n = 750) found that TA-65 supplementation induced moderate telomere elongation, with amplified effects in adults over 60. But telomere elongation did not translate to functional improvements in frailty or inflammation. Long-term carcinogenic potential remains unaddressed. Tier 3: the biology is real, the therapeutic benefit is not yet demonstrated.
Plasma Dilution (Therapeutic Plasma Exchange). A small clinical study found that old plasma dilution reduces human biological age. But a critical review argues that the mechanisms, efficacy, and long-term safety remain incompletely understood, and that the potential removal of protective, anti-geronic components remains poorly characterized. Tier 3: the proof of principle is there, the clinical protocol is not. Bryan Johnson’s publicly documented protocol is instructive here as a tier-placement exercise: his Blueprint stack is, honestly assessed, Tier 1 and Tier 2 interventions bundled with a small number of Tier 3 additions—a genuine self-experiment, tracked and published, sitting exactly where the evidence puts it.
Exosome Therapy. ClinicalTrials.gov lists numerous exosome intervention trials, but the current human evidence is concentrated in aesthetic medicine—skin aging, wrinkles, pigmentation, elasticity. A systematic review identified nine ongoing trials across the United States, Iran, and China, all focused on aesthetic outcomes. Tier 3: the animal data are striking, the human data for systemic aging are embryonic.
Brown Adipose Tissue (BAT) Activation. The VENTURA trial is a 12-week randomized study in older adults testing vibegron for BAT activation. However, a randomized, double-blind, placebo-controlled crossover trial found that 14 days of nitrate supplementation did not increase BAT fat fraction or activation in older adults with type 2 diabetes. The therapeutic protocol is under active investigation.
Follistatin Gene Therapy. A Phase 1/2a trial—CALM-AF-AI—is evaluating the safety and tolerability of intramuscular AAV9-Follistatin gene therapy for counteracting age-related loss of muscle. The mechanism is biologically coherent. The clinical evidence is early. And the field has one high-profile adverse event on record: Bryan Johnson received follistatin gene therapy at an offshore clinic in 2024, developed a severe allergic reaction, and subsequently described the decision as a mistake. That outcome is not an argument against the mechanism. It is a demonstration of where the mechanism currently sits—an intervention with a documented safety signal and no efficacy data.
Epigenetic Reprogramming Without OSK Delivery. Small molecules that modulate epigenetic writers and erasers, or CRISPR-based systems that activate endogenous genes without inserting foreign DNA, are in early preclinical development. The tools exist, the human application does not.
Tier 4: Honestly Crazy, But Theoretically Possible
This is the category where the line between science and science fiction blurs—not because the ideas are absurd, but because the engineering problems are so vast that no one can say with confidence whether they are solvable in centuries or millennia. These are not scams. They are thought experiments with serious intellectual scaffolding, pursued by credentialed researchers and funded by serious institutions. The honest answer to “will this work?” is not “no.” It is “we have no idea—and the only way to find out is to try.”
Cryonics, But the Version Where You’re Not Dead. The word “cryonics” usually means one thing: you die, someone freezes your head or your body in liquid nitrogen, and you hope a future civilization figures out how to thaw you and fix whatever killed you. That version requires you to be dead first. It is the least attractive entry on this entire list, we honestly don’t know whether resurrecting the dead back into this world is even possible, and if it were, would it be the same individual inhabiting the same body, and we don’t honestly know where consciousness goes after the death of an organism, “To sit at my right or left is not for me to grant. These places belong to those for whom they have been prepared by my Father.” (Matthew 20:23), and it is not what this section is about.
There is a different version, and it is already happening in hospitals. It is called therapeutic hypothermia, and it has been standard care for decades. When someone’s heart stops and they are resuscitated, doctors often cool the body to around 5°C—roughly 41°F—for a day or two. The cold slows metabolism, reduces the brain’s demand for oxygen, and limits the damage that reperfusion would otherwise cause. Patients are cooled, kept cold, and rewarmed. They wake up. This is not experimental. It is routine. The reason it works is simple: cold slows biology, and slowing biology buys time.
The problem is that 5°C is not freezing. Water freezes at 0°C, and when it freezes inside a cell, it expands. Ice crystals form, puncture membranes, and shred soft tissue. That is why you cannot simply put a living human in a freezer and expect them to survive. The damage is mechanical, and it is irreversible with current tools. So the question becomes: how close can you get to freezing without crossing the line where ice destroys the tissue?
Closer than you might think. A clinical trial at the University of Maryland is testing a technique called Emergency Preservation and Resuscitation. The patients are trauma victims who arrive at the emergency department after a penetrating injury—a gunshot wound, a stabbing—with no heartbeat. They are, for all practical purposes, dead. The team cools them rapidly, dropping brain temperature into the lower fifties Fahrenheit, and puts the body into a state of suspended animation for up to an hour while surgeons repair the injuries. Then they rewarm the patient and restart the heart. This is not a stasis for months or years. It is a bridge—a way to buy an hour when the clock would otherwise have already run out. But it is reversible, it does not require the patient to stay dead, and it is happening in humans right now.
The next step is doing it without the trauma. Hong Chen’s lab at Washington University in St. Louis induced a reversible torpor-like state in mice and rats—including rats, which do not naturally hibernate—by using focused ultrasound to stimulate the hypothalamus preoptic area, the brain region that regulates body temperature and metabolism. The method is noninvasive and safe in animals, and it targets the central nervous system rather than flooding the body with drugs. The stated goals are exactly what you would want from a “cryonics that keeps you alive”: preserving organs for transplantation, protecting tissue during reduced blood flow, and reducing radiation damage during space travel. The team has published a roadmap for translating the technique to humans. The challenges are metabolic differences between species, dosing, and the reversibility problem. An earlier human trial using hydrogen sulfide was terminated early due to safety concerns, which tells you the field has already hit the translation wall once. The mechanism is demonstrated in animals. The human protocol does not exist yet.
There is also a pharmacological version. A phase 1 clinical trial published in 2026 tested a combination of chlorpromazine and promethazine in 32 patients with acute ischemic stroke. The drug combination induced hypothermia, suppressed brain glucose metabolism, and downregulated plasma markers of aerobic respiration—all without serious adverse events at any dose. The highest dose produced only a modest, transient reduction in body temperature. That tells you how hard it is to push human thermoregulation far without crossing into danger. But the principle is validated: you can pharmacologically push a human brain toward a hypometabolic state, safely, in a controlled clinical setting.
And then there is the wood frog. The North American wood frog freezes solid every winter—heart stops, brain function ceases—and thaws out alive in the spring. It survives because it flushes its cells with glucose before freezing, which acts as a cryoprotectant and prevents ice crystals from forming inside tissues. The human version of this would require water extraction and chemical cryoprotectant injection into every tissue, which is very risky and has never been done. But the biology is proof that a complex vertebrate can survive full metabolic arrest and return. The question is whether the biochemistry can be replicated in an organism that is three orders of magnitude larger and does not have the frog’s evolutionary preparation.
So here is the honest framing. The cryonics that keeps the organism alive—metabolically paused, revivable, not dead—is not science fiction. It is a research program with clinical trials, animal models, and a clear mechanistic rationale. The Maryland trial is doing it right now, for an hour. Synthetic torpor is doing it in rats, reversibly. Drug-induced hypothermia is doing it in human stroke patients, safely. What does not exist is the duration. No one has kept a human metabolically suppressed for months or years and then brought them back. The frog does it for a season. The bear does it for a winter. The human protocol is being built, and the building blocks are real. But the long-duration version—the version that would let you sleep through a century of scientific progress—remains theoretically possible, biologically grounded, and not yet demonstrated.
The Fringe of Regenerative Medicine: Induced Blastemas, Decellularized Scaffolds, and the Dream of Regrowing What Was Lost. Humans are not planarians. But they are not entirely non-regenerative either. Digit tips regrow in young children (Illingworth, 1974). The liver restores its mass after partial resection. The blueprint for regeneration exists in the human genome—it is simply silenced, presumably because the same pathways that permit controlled dedifferentiation and proliferation are the pathways that, when dysregulated, produce cancer (Tanaka & Reddien, 2011). The evolutionary trade-off was explicit: humans traded regenerative capacity for tumor suppression.
The fringe ambition is to reverse that trade-off—locally, temporarily, and under strict control. Blastema induction: MRL mice regenerate ear punch wounds without scarring and show enhanced cardiac and digit regeneration (Godwin et al., 2013). p21 knockout mice regenerate digit tips and ear tissue (Bedelbaeva et al., 2010). Decellularized organ scaffolds—stripping a donor organ of its cells and reseeding the remaining extracellular matrix with patient-derived stem cells—are already in early human trials for trachea, esophagus, and vascular grafts (Badylak et al., 2009). 3D bioprinting of vascularized tissue is still confined to small, simple structures. No human has regrown a limb. But the biology is not magic. It is a silenced program, and programs can be re-expressed. Biologically grounded, no human protocol, and the only intervention on this list that requires you to grow something rather than buy it.
Whole-Body Replacement, Piece by Piece. Jean Hébert, a neuroscientist hired by ARPA-H, has outlined a roadmap for replacing the body’s tissues with lab-grown equivalents—and the deepest insight in the proposal is not the technology. It is the observation that the body is already replacing itself. The intestinal epithelium turns over every three to five days. The epidermis renews every four weeks. Red blood cells are recycled every 120 days. Even bone is in constant remodeling—a slow metabolic churn that replaces the skeleton roughly every ten years. The body is not a static object that ages. It is a process that maintains itself, and the failure of that maintenance is what we call aging (López-Otín et al., 2023).
The Hébert proposal takes this seriously. If the body is a self-replacing system whose replacement machinery degrades, then the intervention is not to build a new body from scratch—it is to accelerate and redirect the turnover that is already occurring (Hébert, 2024). Replace the heart with a lab-grown heart. Replace the kidneys. Replace the liver, the lungs, the pancreas, the vasculature, the skin, the connective tissue. Each replacement is a discrete surgical event, not a single catastrophic intervention. The body becomes a Ship of Theseus not by philosophical fiat but by ordinary surgery performed on a schedule the organism was already keeping.
This subject can go really dark, really fast without ethical rigor and strict research discipline. Keep this science regulated and in the hands of the Good Guys.
Not only is there a risk of human rights violations and serious organized crime regarding trade in organs and human tissues, also research on brain organoids is fraught with ethical hazards. Strict enforcement of an unyielding rulebook is absolutely, positively necessary in this field. No buts “But I want to be a Nazi!” No.
The brain is the hard problem. Hébert’s proposal is not to transfer the mind to a new substrate, but to gradually replace the brain itself—neuron by neuron, region by region—while preserving the pattern of connections that constitutes memory and identity (Hébert, 2024). The conceptual objection is that the brain is not a collection of interchangeable parts. The engineering objection is that no one has the faintest idea how to do this. But the roadmap exists, it is published, and it is funded. A 2026 perspective in Aging Cell, co-authored by researchers from Harvard, the Buck Institute, and the Salk Institute, proposed a formal research agenda for what it calls “replacement-based ageing interventions” as a class of therapies capable of “systemic and sustained rejuvenation” (Lore et al., 2026). Tier 4: biologically continuous, surgically incremental, and the only intervention on this list that begins with the observation that you are already doing it.
Xenotransplantation (Genetically Modified Pig Organs). Gene-edited porcine kidneys have supported living human recipients under intensive immunosuppression. A 71-year-old man in China lived for nearly six months after receiving a liver from a genetically modified pig. Preclinical work has shown that multiplex genome edits can sustain life-supporting renal graft function in non-human primates for many months (Tenajas & Miraut, 2025). But the porcine organs age more rapidly than human organs; a pig heart in a human body is still a pig heart, with a pig’s lifespan. Unless the organ itself can be rejuvenated, the transplant buys function, not decades (FASEB, 2026). Clinically real, therapeutically limited, and a bridge to something more radical.
Nanomedicine and Molecular Repair. Nanoparticle-based senolytic therapies are already in preclinical development, with surface ligands that promote cellular uptake and components responsive to lysosomal β-galactosidase, acidic pH, reactive oxygen species, or protease activity to regulate cargo release (Nanoparticle-based senolytic therapies, 2026). The translational challenges are real: senescent-cell heterogeneity, immunotoxicity, delayed organ injury in older hosts, and reproducible manufacturing at scale. The delivery systems are being built.
Nanobots: Molecular Machines That Repair You From the Inside. The nanobot—an autonomous, molecular-scale machine capable of navigating the bloodstream, identifying damaged tissue, and performing mechanosynthesis or molecular repair—is the most audacious idea in the entire inventory. It is also the one most often dismissed as science fiction. That dismissal is half right and entirely lazy.
The distinction that matters is between nanoscale machines and nanoscale manufacturing. The first already exists. DNA origami—the folding of long single-stranded DNA into arbitrary two- and three-dimensional shapes with addressable attachment sites—was demonstrated nearly two decades ago (Rothemund, 2006). DNA nanorobots capable of autonomous cargo delivery have been built and tested in animals: a 2018 study in Nature Biotechnology demonstrated a DNA nanorobot that opens only when it encounters a specific tumor-associated protein, delivering thrombin to the tumor vasculature and inducing localized thrombosis in mouse models of breast cancer, melanoma, and lung cancer, with no effect on normal tissue (Li et al., 2018). Magnetic microrobots have been steered through blood vessels and used for localized drug delivery (Nelson et al., 2010). The 2016 Nobel Prize in Chemistry was awarded for the design and synthesis of molecular machines (Sauvage, Stoddart, & Feringa, 2016).
What does not exist is the Drexlerian assembler—the diamondoid molecular manufacturing system capable of building arbitrary structures atom by atom (Drexler, 1986; Drexler, 1992). That vision was attacked by Richard Smalley on the grounds that mechanosynthesis in solution is defeated by the “fat fingers” and “sticky fingers” problems (Smalley, 2001). Freitas countered with the proposal of a diamondoid mechanosynthetic assembler operating in vacuum (Freitas, 1999), and the debate has never been resolved empirically, because no one has built the thing. Tier 4: half real, half aspiration, and the honest answer to “will it work?” is “the delivery systems are already working; the repair machines are not.”
Tier 5: Scientifically Fringe—No Evidence Base, No Near-Term Translation
The criterion for this tier is not danger. It is epistemic status. These are claims that may be true, may be false, and cannot currently be distinguished—because the experiments do not exist, the instruments do not exist, or the claims are structured in a way that no available experiment could adjudicate them. Some are peer-reviewed. Some are funded. Some are actively pursued by credentialed researchers. None has produced a human outcome that any regulatory body would recognize.
Germline Genome Editing for Longevity. In 2018, He Jiankui edited the CCR5 gene in human embryos, resulting in the birth of twin girls, and was subsequently imprisoned. The scientific question raised by that episode is not whether embryo editing is possible—it plainly is—but whether any longevity target exists that would justify it. The answer is no. There are no validated longevity alleles with effect sizes large enough to warrant germline intervention, the pleiotropy of aging-associated genes is poorly mapped, and the edit would be present in every cell of the resulting person forever, including their germ cells (Lanphier et al., 2015; National Academies, 2017). The tools work. The target list does not exist.
Whole-Genome Synthesis and Synthetic Minimal Cells. In 2016, researchers at the J. Craig Venter Institute reported JCVI-syn3.0, a bacterial cell with a chemically synthesized genome reduced to 473 genes—the smallest genome of any self-replicating organism (Hutchison et al., 2016). The GP-write consortium has since proposed synthesizing a human genome from scratch. The science is real and advancing. The longevity application is entirely hypothetical: if you can specify a genome, you can in principle specify an aging program. But no one has specified one, and the regulatory apparatus for a synthetic human genome does not exist.
Xenobots and Anthrobots. In 2020, researchers reported that embryonic cells from Xenopus laevis could self-assemble into motile, self-healing biological entities—”xenobots”—capable of coordinated movement and cargo transport (Kriegman et al., 2020). In 2023, the same group showed that human tracheal epithelial cells could self-assemble into “anthrobots” that move through tissue and promote neuronal wound healing (Gumuskaya et al., 2023). These are published, replicated, and genuinely novel. They are also not therapies. A robot built from your own cells that repairs your tissue is a beautiful proof of concept with no clinical pathway, no dosing, no durability data, and no manufacturing model.
Ancestral Gene Resurrection. Colossal Biosciences is pursuing mammoth-like phenotypes through comparative genomics and multiplex editing. The longevity version of the idea is that ancestral alleles—from long-lived clades or from hominins with different aging trajectories—could be reintroduced to slow human aging. Comparative genomics is a real discipline with real findings. The causal alleles are not identified, the effect sizes are unknown, and the pleiotropic consequences of resurrecting a silenced regulatory network in a modern genome are entirely unmapped.
Quantum Biology of Aging. When you see the word “quantum” attached to anything about aging, your instinct should be suspicion. You are usually right. Quantum frequency medicine, quantum coherence water, quantum detox—the word has been used to sell nonsense for decades, and the instinct to roll your eyes is a good one.
But there is a real field underneath the marketing, and it has nothing to do with any of that. It is called quantum biology, and it studies the places where living systems appear to rely on quantum effects—tunneling, coherence, superposition—to do ordinary biological work. A 2026 review in Clinical and Translational Medicine titled “Quantum biology: From mechanisms to medicine” surveys the field across photosynthesis, enzyme catalysis, DNA base pairing, sensory systems, and mitochondrial electron transport (Sung & Cheong, 2026). The mechanisms it describes are not metaphors. They are measurable, and three of them are directly relevant to how you age.
Start with the most unsettling one: some of your mutations may be quantum events. In the 1960s, Per-Olov Löwdin proposed that protons can tunnel along the hydrogen bonds holding DNA’s two strands together—not climb over the energy barrier, but pass through it, the way a quantum particle can appear on the far side of a wall it lacks the energy to climb. When that happens, a base pair briefly changes shape, adopting a form called a tautomer. If the cell replicates during that window, the wrong base gets paired, and the result is a mutation (Löwdin, 1965, as cited in Mutation in DNA, 2025). This is not a fringe idea; it is a cornerstone of the field. A 2025 paper in BioSystems calculated mutation probabilities from proton transfer in the adenine-thymine base pair and found results consistent with the existing literature (Mutation in DNA, 2025). A 2026 PLOS ONE paper modeling DNA as a quantum system reached the same conclusion (DNA as a quantum system, 2026). And a 2026 Open Quantum Systems analysis put the tautomeric occupation probability at 1.73 × 10⁻⁴—a figure that, in the authors’ words, “may well play a far more important role in DNA mutation than has hitherto been suggested” (Open Quantum Systems, 2026). If any of this holds, then some fraction of the mutations driving cancer and aging are not classical chemistry. They are quantum mechanics.
Now the mitochondria. Electron tunneling is not a metaphor for how mitochondria work—it is how they work. Long-range electron tunneling occurs in many proteins, helped along by aromatic residues that appear frequently in oxidoreductases, the key enzymes in the respiratory chain (The quantum mitochondrion, 2016). That tunneling keeps electron flow tightly coupled to proton pumping through a process called redox tuning (The quantum mitochondrion, 2016). When the coupling degrades, the system leaks. The 2026 review states it plainly: in mitochondria, quantum decoherence disrupts electron transport chain redox coupling, raising reactive oxygen species and accelerating aging, metabolic dysfunction, and cancer progression (Sung & Cheong, 2026). That is a mechanistic claim about aging, not a slogan.
Protein folding is the least developed of the three, and honesty requires saying so. A 2012 paper in Science China Life Sciences argued that the relationship between folding rate and temperature implies quantum tunneling between protein conformations—that the motion of a folding protein has a quantum character (Luo, 2012). A 2017 follow-up in Quantitative Biology derived folding rate equations from first principles and proposed experimental tests (Luo, 2017). The field is small. The debate is live. The therapeutic applications are nonexistent.
What ties this together is the therapeutic framing now being proposed. The 2026 review outlines “quantum-informed medicine”—diagnostics like coherence lifetime sensors and tunneling-based mutational signatures, and therapeutics like mitochondrial redox modulators and DNA-stabilizing agents that target the quantum foundations of health and disease (Sung & Cheong, 2026). A separate 2025 review proposes that electromagnetic field stimulation of intrinsically disordered proteins may work partly through quantum tunneling effects on interfacial water (Electromagnetic Field Stimulation, 2025). None of this has been validated in humans. But it is a framework—mechanistically specified, experimentally testable, and actively published.
n = 1 Self-Experimentation Without Assay. Josiah Zayner’s 2017 CRISPR self-injection targeting the MYOSTATIN gene is the canonical case, and its scientific status is precise. It was unreplicated, uncontrolled, unmeasured, and unpublished. Zayner reported no muscle gain and never produced data (Zayner, 2017). The scientific critique is not that the act was reckless—it is that it produced nothing. An n = 1 experiment with no assay, no baseline, no control, and no publication is not a data point. It is an anecdote. The same applies to the wider literature of self-administered gene therapies, DIY fecal transplants, and unmeasured supplement stacks that circulate as “citizen science” (Guerrini et al., 2018). They occupy the cultural space of science while contributing none of its substance.
Sorry, Josiah. Your experiment was FUN, but it should be replicable.
Unregulated Stem Cell and Young Plasma Interventions. These belong in Tier 5 on scientific grounds alone. The published human evidence for systemic rejuvenation from autologous or allogeneic stem cell infusions is absent. The published human evidence for young plasma infusion is a single small trial showing no cognitive benefit, and the FDA issued a safety communication in 2019 stating that these infusions have no proven clinical benefit (FDA, 2019). The parabiosis literature in mice is real and interesting; the human translation is not there.
Failed Hypotheses That Persist. Resveratrol activated sirtuins in vitro, extended lifespan in yeast and worms, and failed to improve metabolic outcomes in randomized, placebo-controlled trials of overweight and obese humans (van der Made et al., 2015). The hypothesis was elegant. The trials were negative. Scientifically, the file is closed until new data arrive. Tier 5: a settled negative result that the market has not settled.
The Honest Assessment
Here is what the landscape actually looks like. Rapamycin, senolytics, NAD+ precursors, MSCs, Klotho gene therapy, and OSK reprogramming are in human trials. Some show functional benefits. None have demonstrated lifespan extension in humans.
Tier 3 is where intellectual honesty lives—interventions where the mechanism is plausible but the human data are absent or contradictory, and where the honest answer is “we do not know yet.” Bryan Johnson’s publicly tracked protocol sits exactly here in tier terms: a rigorous bundle of Tier 1 and Tier 2 interventions, plus Tier 3 additions, with one documented Tier 3 adverse event that the field should treat as data rather than embarrassment.
Tier 4 is where the long game is played—cryonics, induced regeneration, whole-body replacement, xenotransplantation, nanomedicine, and nanobots. These are not frauds. They are bets. The honest answer to whether they will work is not “yes” or “no.” It is “the only way to find out is to stay alive long enough to try.”
Tier 5 is where the epistemic floor drops out—germline editing with no validated target, synthetic genomes with no application, xenobots with no clinic, ancestral resurrection with no causal alleles, quantum mechanisms with no intervention, unfalsifiable cosmologies, and self-experiments that generate no data. The distinction between Tier 4 and Tier 5 is not ambition. It is whether the claim can, in principle, be tested and can, in principle, produce knowledge. Tier 4 claims can. Tier 5 claims, as currently constituted, cannot.
And notice what the most grounded of these bets has in common with the Tier 1 interventions. Whole-body replacement works because the body already replaces itself. Exercise works because it signals the maintenance machinery to keep running. Sleep works because it is when the repairs are consolidated. Social connection works because it regulates the stress axis that otherwise degrades the repair systems. The tiered protocol and the tiered medicine are not separate projects. They are the same project—one pursued with behavior, the other with molecules.
The interventions that actually extend lifespan in humans—exercise, sleep, social connection, avoidance of chronic stress—remain Tier 1, free, and unfashionable. The pharmacological arsenal is real, and it is advancing. But it is not a substitute for the behavioral foundations. It is an adjunct.
The assembly line wants you to believe that longevity is a product you buy, a protocol you inject, a subscription you maintain. It is not. It is a developmental trajectory you author. The drugs are coming. The biology is real. But the main event is still the main event—and it still starts the moment you stop waiting for permission.
References
Badylak, S. F., Taylor, D., & Uygun, K. (2009). Whole-organ tissue engineering: Decellularization and recellularization of three-dimensional matrix scaffolds. Annual Review of Biomedical Engineering, 13, 27–53.
Bedelbaeva, K., Snyder, A., Gourevitch, D., Clark, L., Zhang, X. M., Leferovich, J., Cheverud, J. M., Lieberman, P., & Heber-Katz, E. (2010). Lack of p21 expression links cell cycle control and appendage regeneration in mice. Proceedings of the National Academy of Sciences, 107(13), 5845–5850.
Best, B. P. (2008). Scientific justification of cryonics practice. Rejuvenation Research, 11(2), 493–503.
Dittus, M., Reddy, A., Sharif, D., & Joshi, A. (2026). Novel senolytic clinical trial in CVID with GLILD. Journal of Human Immunology, 2(CIS2026), eCIS2026abstract.223.
Drexler, K. E. (1986). Engines of creation: The coming era of nanotechnology. Anchor Press.
Drexler, K. E. (1992). Nanosystems: Molecular machinery, manufacturing, and computation. Wiley.
Ettinger, R. (1964). The prospect of immortality. Doubleday.
FASEB. (2026). Sirolimus and mimetics: Modulator sine qua non for cardiac xenotransplantation? The FASEB Journal. Advance online publication.
FDA. (2019). Safety communication: Young donor plasma infusions. U.S. Food and Drug Administration.
Freitas, R. A. (1999). Nanomedicine, Volume I: Basic capabilities. Landes Bioscience.
Godwin, J. W., Pinto, A. R., & Rosenthal, N. A. (2013). Macrophages are required for adult salamander limb regeneration. Proceedings of the National Academy of Sciences, 110(23), 9415–9420.
Guerrini, C. J., Spencer, G. E., & Zechiedrich, L. (2018). Diy CRISPR: Biohacking and the ethics of self-experimentation. The CRISPR Journal, 1(3), 193–197.
Gumuskaya, G., Srivastava, P., Cooper, B. G., Lesser, H., Semegran, B., Garnier, S., & Levin, M. (2023). Motile living biobots self-construct from adult human somatic progenitor seed cells. Advanced Science, 11(4), 2303575.
Hébert, J. (2024). Replacing aging. [Book].
Hutchison, C. A., Chuang, R. Y., Noskov, V. N., Assad-Garcia, N., Deerinck, T. J., Ellisman, M. H., … & Venter, J. C. (2016). Design and synthesis of a minimal bacterial genome. Science, 351(6280), aad6253.
Illingworth, C. M. (1974). Trapped fingers and amputated finger tips in children. Journal of Pediatric Surgery, 9(6), 853–858.
Justice, J. N., et al. (2026). Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: A proof-of-principle randomized, controlled trial. Nature Metabolism. Advance online publication.
Klothea Bio. (2026, February 19). Klothea Bio launches Phase 1b trial of AKL003 alpha Klotho mRNA therapy in healthy adults. PackGene Biotech.
Kriegman, S., Blackiston, D., Levin, M., & Bongard, J. (2020). A scalable pipeline for designing reconfigurable organisms. Proceedings of the National Academy of Sciences, 117(4), 1853–1859.
Lanphier, E., Urnov, F., Haecker, S. E., Werner, M., & Smolenski, J. (2015). Don’t edit the human germ line. Nature, 519(7544), 410–411.
Li, S., Jiang, Q., Liu, S., Zhang, Y., Tian, Y., Song, C., … & Ding, B. (2018). A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo. Nature Biotechnology, 36(3), 258–264.
Life Biosciences. (2026, February). FDA OKs risky, pioneering OSK rejuvenation trial with Sinclair’s ER-100. The Niche.
Lore, S., et al. (2026). Replacement-based ageing interventions for systemic rejuvenation: Shaping longevity science and clinical directions. Aging Cell, 25(5), e70516.
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2023). Hallmarks of aging: An expanding universe. Cell, 186(2), 243–278.
Martens, C., Decker, K., DeConne, T., et al. (2026). A Phase-II randomized controlled pilot study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment. Alzheimer’s and Dementia, 22(7), e71605.
Mayo Clinic. (2026, September 18). Rapamycin in frail older subjects with heart failure with preserved ejection fraction. Mayo Clinic Proceedings. Advance online publication.
Mitrix Bio. (2026). Announcing first-in-history human safety trials of full-body mitochondrial transplantation.
Nanoparticle-based senolytic and senomorphic therapies for healthy aging: Design principles, translational evidence, and challenges. (2026). Ageing Research Reviews. Advance online publication.
National Academies of Sciences, Engineering, and Medicine. (2017). Human genome editing: Science, ethics, and governance. National Academies Press.
Nelson, B. J., Kaliakatsos, I. K., & Abbott, J. J. (2010). Microrobots for minimally invasive medicine. Annual Review of Biomedical Engineering, 12, 55–85.
NMNH-Ca Study Group. (2026). Safety and exploratory efficacy of reduced β-nicotinamide mononucleotide calcium salt (NMNH-Ca) in healthy middle-aged and older adults: A randomized, double-blind, placebo-controlled trial. Europe PMC.
RAP PAC Study Group. (2026). Rapalog pharmacology (RAP PAC) study. ClinicalTrials.gov Identifier: NCT05949658.
Rothemund, P. W. K. (2006). Folding DNA to create nanoscale shapes and patterns. Nature, 440(7082), 297–302.
Sauvage, J.-P., Stoddart, J. F., & Feringa, B. L. (2016). The Nobel Prize in Chemistry 2016: Design and synthesis of molecular machines. Royal Swedish Academy of Sciences.
Smalley, R. E. (2001). Of chemistry, love and nanobots. Scientific American, 285(3), 76–77.
Su, X., Wang, C., Gou, Z., & Qu, Y. (2025). Effects of TA-65 on telomere length, functional outcomes, and inflammation: A systematic review and meta-analysis. Cell Biology and Toxicology.
Tanaka, E. M., & Reddien, P. W. (2011). The cellular basis for animal regeneration. Developmental Cell, 21(1), 172–185.
Tenajas, R., & Miraut, D. (2025). Organ transplants, hype, and what patients need to know. BMJ, 390, r1884.
UT Health San Antonio. (2026, March 25). UT Health San Antonio launches clinical trial to study rapamycin and healthy aging.
van der Made, S. M., Plat, J., & Mensink, R. P. (2015). Resveratrol does not influence metabolic risk markers related to cardiovascular health in overweight and obese subjects: A randomized, placebo-controlled, crossover trial. PLoS ONE, 10(4), e0124307.
VENTURA Trial Group. (2026). Vibegron for ENergy Thinking and Resilience in Aging (VENTURA). ClinicalTrials.gov Identifier: NCT06987383.
Zayner, J. (2017). DIY CRISPR: How I edited my own genome. [Self-published].